Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral ibandronic acid.

Luigi Gennari1

  • 1University of Siena, Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, Policlinico Le Scotte, 53100-Siena, Italy. gennari@unisi.it

Idrugs : the Investigational Drugs Journal
|February 8, 2005
PubMed
Summary

Roche is developing an oral bisphosphonate formulation of ibandronic acid for treating bone metastases in breast cancer patients. This treatment is also being developed for osteoporosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis associated with pregnancy and lactation (PLO): can REMS have a role in prevention and follow-up?

Endocrinology, diabetes & metabolism case reports·2026
Same author

Across Clinical Profiles of Cardiorenal-Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach.

Biomedicines·2026
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Burosumab an emerging therapy in TIO: a local clinical survey and a systematic review with individual patient data analysis.

Frontiers in endocrinology·2026
Same author

Association of Sport Participation and Calcium Intake with Bone Mineral Density in Children and Adolescents: A Cross-Sectional Study.

Children (Basel, Switzerland)·2026
Same author

Correction: Vitamin D intake in Italian healthy subjects and patients with different pathological disorders.

Frontiers in nutrition·2026

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Metastatic bone disease is a common complication of breast cancer, leading to significant morbidity.
  • Bisphosphonates are a class of drugs used to treat bone diseases.
  • Ibandronic acid is a nitrogen-containing bisphosphonate derivative.

Purpose of the Study:

  • To evaluate the efficacy and safety of an oral formulation of ibandronic acid.
  • To assess its potential as a treatment for metastatic bone disease in breast cancer.
  • To develop the formulation for osteoporosis treatment.

Main Methods:

  • Development of an oral formulation of ibandronic acid.
  • Clinical trials investigating its use in breast cancer patients with bone metastases.
  • Collaborative development with GlaxoSmithKline plc and Chugai Pharmaceutical Co Ltd.

Main Results:

  • Filing for indication in October 2002 for metastatic bone disease in breast cancer.
  • Development for osteoporosis treatment in parallel.

Conclusions:

  • Oral ibandronic acid shows potential for treating bone metastases in breast cancer.
  • The formulation is also being developed for osteoporosis, indicating broader therapeutic applications.

Related Experiment Videos